TomoTherapy Announces First Middle East Installation of Hi·Art® Cancer Treatment System

Saudi Arabia`s renowned King Faisal Specialist Hospital & Research Centre will
become region`s first to treat cancer patients with next-generation radiation
therapy solution
MADISON, Wis.--(Business Wire)--
TomoTherapy Incorporated (NASDAQ: TOMO) announced today that Saudi Arabia`s
leading cancer center, King Faisal Specialist Hospital & Research Centre
(KFSH&RC) in Riyadh, will become the region`s first to treat patients with the
Hi·Art® treatment system, a next-generation radiation therapy solution designed
to improve the precision of cancer care. KFSH&RC commemorated the historic
Hi·Art treatment system installation in a ribbon-cutting ceremony during a
scientific meeting held at the hospital March 9-12, 2009.

The meeting, entitled "Innovative Approaches in Radiotherapy: Beyond Tomorrow",
attracted radiation oncology professionals from throughout the country and
featured an impressive roster of speakers, including TomoTherapy co-founder and
Chairman of the Board Thomas "Rock" Mackie, Ph.D.

"It was an honor for me to attend both the scientific meeting and Hi·Art system
opening ceremony hosted by King Faisal Specialist Hospital & Research Centre,"
said Dr. Mackie. "TomoTherapy is extremely pleased to partner with this
world-renowned centre as it implements the only solution designed to deliver on
the promises of image-guided, intensity-modulated radiation therapy (IG-IMRT)."

TomoTherapy`s Hi·Art treatment system is unique among radiation therapy devices
in its computed tomography (CT) scanner-based design. The system allows
clinicians to efficiently acquire a true CT image of the patient immediately
before daily treatment to help ensure accuracy. Then, using the same equipment
as used in imaging, the treatment team can deliver highly-precise radiation in a
continuous, 360-degree (helical) pattern.

"We look forward to employing TomoTherapy® treatment technology to benefit our
patients in terms of minimization of dose to normal tissue and improvement of
side-effect related outcomes," said Dr. Mohammad Al-Shabanah, Section Head,
Radiation Oncology, KFSH&RC. "One area of interest for us is the use of total
marrow irradiation to support our large bone marrow transplant program."

Added Dr. Belal Moftah, Chairman, Department of Biomedical Physics, KFSH&RC: "We
are very excited at King Faisal Specialist Hospital & Research Centre to open
our TomoTherapy unit, which is the first in the Middle East. We plan on
maximizing the advantages of integrated CT imaging and highly-modulated beam
delivery that TomoTherapy provides. Additionally, we are extremely satisfied
with the speed of installation and professionalism of both TomoTherapy and its
distribution partner in Saudi Arabia, Attieh Medico."

About King Faisal Specialist Hospital & Research Center

King Faisal Specialist Hospital & Research Center (KFSH&RC) is an 894-bed
multi-facility, multi-entity tertiary care hospital and one of the leading
healthcare institutions in the Kingdom of Saudi Arabia. Its mission is to
provide medical services of a highly-specialized nature and to promote medical
research and education programs, including postgraduate education training, as
well as to contribute to the prevention of disease.

About Attieh Medico

Attieh Medico, Ltd., is a leading medical technology company in the Kingdom of
Saudi Arabia, representing various internationally-renowned manufacturers of a
wide range of high-tech, state-of-the-art medical equipment. Attieh Medico
assumed responsibility for supplying and maintaining the innovative TomoTherapy
Hi·Art® cancer treatment system in June 2008. For more information on Attieh
Medico, please visit AttiehMedico.com.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy®
Hi·Art® treatment system, an advanced radiation therapy system for the treatment
of a wide variety of cancers. The Hi·Art treatment system combines integrated CT
imaging with conformal radiation therapy to deliver sophisticated radiation
treatments with speed and precision while reducing radiation exposure to
surrounding healthy tissue. The company`s stock is traded on the NASDAQ Global
Select Market under the symbol TOMO. To learn more about TomoTherapy, please
visit TomoTherapy.com.

©2009 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, the
TomoTherapy logo and Hi·Art are among trademarks, service marks or registered
trademarks of TomoTherapy Incorporated in the United States and other countries.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5925085&lang=en

TomoTherapy Incorporated
Investor Contact:
Stephen C. Hathaway
Chief Financial Officer
608.824.2800
shathaway@tomotherapy.com
or
Media Contact:
Kevin O`Malley
Manager, Corporate Communications
608.824.3384
komalley@tomotherapy.com

Copyright Business Wire 2009